Bristol-Myers Gets Europe OK for Sprycel in Form of Leukemia

Datum : 11/02/2019 @ 13h47
Quelle : Dow Jones News
Name : Bristol Myers Squibb Co (BMY)
Kurs : 59.72  -0.09 (-0.15%) @ 01h58
Bristol Myers Squibb share price Chart
After Hours
Last Trade
Last $ 59,89 ▲ 0,17 (0,28%)

Bristol-Myers Gets Europe OK for Sprycel in Form of Leukemia

Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart


Von Mai 2018 bis Mai 2020

Click Here for more Bristol Myers Squibb Charts.
   By Colin Kellaher 
 

Bristol-Myers Squibb Co. (BMY) on Monday said the European Commission approved the company's Sprycel in combination with chemotherapy for children with a form of leukemia.

The New York biopharmaceutical company said the approval covers the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia and includes both the tablet and powder formulations.

Bristol-Myers said the approval marks the second pediatric leukemia indication for Sprycel in Europe.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

February 11, 2019 07:32 ET (12:32 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Kürzlich von Ihnen besucht
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

Der Markt LS (Lang&Schwarz) wird als Realtime Indikation kostenlos angezeigt und bietet Ihnen außerbörsliche Realtime Aktienkurse in der Zeit von Mo-Fr 08:00 bis 23:00, Samstags 10:00 bis 13:00 und Sonntags an.
NYSE und AMEX Kurse sind um mindestens 20 Minuten zeitverzögert.
Alle weiteren Kurse sind um mindestens 15 Minuten zeitverzögert, sofern nicht anders angegeben.
P: V:de D:20200531 10:45:09